引用本文
  • 刘建军,谷磊.坦索罗辛在输尿管结石治疗中对急性肾绞痛发生的预防价值[J].同济大学学报(医学版),2016,37(3):112-117, 128.    [点击复制]
  • LIU Jian-jun,GU Lei.Roles of tamsulosin in relief of renal colic and clearance of ureteral calculi:a meta-analysis of randomized controlled trials[J].同济大学学报(医学版),2016,37(3):112-117, 128.   [点击复制]
【打印本页】 【在线阅读全文】【下载PDF全文】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 435次   下载 439 本文二维码信息
码上扫一扫!
坦索罗辛在输尿管结石治疗中对急性肾绞痛发生的预防价值
刘建军,谷磊
0
(上海市静安区市北医院重症医学科,上海 200443)
摘要:
目的 评价坦索罗辛在治疗输尿管结石过程中再发绞痛及排石情况。方法 计算机检索PubMed、EMbase、Cochrane database、CBMdisc、CNKI和万方等数据库,检索所有关于坦索罗辛治疗输尿管结石过程中发生肾绞痛的随机对照试验(RCT),检索时限均为建库至2015年5月30日。同时手检纳入文献的参考文献。按纳入排除标准由两人独立进行RCT的筛选、资料提取和质量评价后,采用RevMan 5.3进行Meta分析。结果 纳入13项随机对照研究研究,其中坦索罗辛组656例,对照组655例。Meta分析显示:(1) 在肾绞痛再发生率方面: 与对照组相比,坦索罗辛组的肾绞痛再发风险明显降低[RR=0.45,5%CI(0.31,0.65)],其中下段及上段输尿管绞痛发生率分别降低了57%[RR=0.43,5%CI(0.27,0.67)]和46%[RR=0.54,5%CI(0.34,0.85)]。(2) 在结石排出率方面: 与对照组相比,坦索罗辛组的结石排出率明显增加[RR=1.67,5%CI(1.40,1.99)]。亚组分析显示坦索罗辛对于下段输尿管结石的排出率增加了75%[RR=1.75,5%CI(1.45~2.13)],而在上段输尿管排石率方面无明显差异。(3) 在结石排出时间方面: 与对照组相比,坦索罗辛组的结石排出时间明显降低[MD=-4.45, 95%CI(-5.20,-3.70)],其中下段及上段输尿管的排出时间分别降低3.75d[MD=-4.75,5%CI(-5.77,-3.73)]和2.20d[MD=-3.20,5%CI(-4.71,-1.69)]。结论 坦索罗辛有助于输尿管结石过程中再发绞痛的预防、促进结石排出,因原始研究数量尚少,建议临床上审慎使用,需要更多高质量、大样本的RCT 进一步论证。
关键词:  输尿管结石  坦索罗辛  肾绞痛  Meta分析
DOI:10.16118/j.1008-0392.2016.03.023
投稿时间:2015-05-24
基金项目:
Roles of tamsulosin in relief of renal colic and clearance of ureteral calculi:a meta-analysis of randomized controlled trials
LIU Jian-jun,GU Lei
(Dept. of Intensive Care Unit, Shibei Hospital, Zhabei Disttrict, Shanghai 200443, China)
Abstract:
Objective To evaluate the roles of tamsulosin in decreasing incidence of recurrent renal colic and clearance of ureteral calculi. Methods PubMed, Embase, Cochrane, CBMdisc, CNKI and Wanfang database were searched from their establishment to May 2015 for collecting randomized controlled trials(RCTs) of tamsulosin in treatment of renal colic. Meanwhile, the enrolled references from those RCTs were retrieved manually. According to inclusion and exclusion criteria, two independent researchers screened RCTs and evaluated the quality. Then, a meta-analysis was conducted with RevMan 5.3. Results Thirteen RCTs of tamsulosin in treating ureteral calculi were included for meta-analysis, in which 656 patients in tamsulosin group and 655 patients in control group were involved. The results of meta-analyses showed that:(1) Compared with control group, tamsulosin reduced risk of recurrent renal colic significantly during drug therapy of ureteral calculi[RR=0.45,5%CI(0.31,0.65)]and the risk was decreased by 57% and 46% in lower ureteral calculi[RR=0.43,5%CI(0.27,0.67)]and upper ureteral calculi[RR=0.54,5%CI(0.34,0.85)], respectively.(2) Compared with control group, tamsulosin increased the clearance rate of ureteral calculi significantly[RR=1.67,5%CI(1.40,1.99)]. And the clearance rate of lower ureteral calculi was increased by 75%[RR=1.75,5%CI(1.45,2.13)], while there was no significant change for upper ureteral calculi.(3) Compared with control group, tamsulosin reduced clearance time of calculi significantly[MD=-4.45,5%CI(-5.20,-3.70)], and the clearance time was reduced by 3.75 and 2.20 days in lower ureteral calculi[MD=-4.75,5%CI(-5.77,-3.73)]and upper ureteral calculi[MD=-3.20,5%CI(-4.71,-1.69)], respectively. Conclusion The current evidence demonstrates that tamsulosin can decrease the incidence of recurrent renal colic and accelerate the clearance of ureteral calculi during drug therapy of ureteral calculi. Due to a small amount of original studies, it is suggested to prescribe tamsulosin with prudence. More RCTs with higher quality and larger samples are needed.
Key words:  ureteral calculi  tamsulosin  renal colic  meta-analysis

您是第5128646位访问者
版权所有《同济大学学报(医学版)》编辑部
主管单位:教育部 主办单位:同济大学
地  址: 上海四平路1239号 邮编:200092 电话:021-65980705 E-mail: yxxb@tongji.edu.cn
本系统由北京勤云科技发展有限公司设计